UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (date of earliest event reported): October 2, 2015

 

LION BIOTECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

	NEVADA
	(State of Incorporation)

 

 

001-36860		75-3254381
(Commission File Number)		(I.R.S. Employer Identification No.)

 

112 W. 34th Street, 17th Floor, New York, NY		10120
(Address of Principal Executive Offices)		(Zip Code)

 

 

	(212) 946-4856
	(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

  

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On October 2, 2015, Laszlo Radvanyi resigned as Chief Scientific Officer of Lion Biotechnologies, Inc.

 

 

 

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		LION BIOTECHNOLOGIES, INC.
Date:	May 27, 2016	By:	/s/ Molly Henderson
			Molly Henderson, Chief Financial Officer